Shares of Pharvaris N.V. (PHVS) surged 5.94% on Friday, marking a strong finish to the trading week for the biopharmaceutical company. The stock's intraday surge came amid bullish analyst sentiment.
Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Pharvaris and set a price target of $34.00, reflecting a significant upside potential from current levels. The analyst's positive outlook appears to be fueling investor optimism and driving the stock higher.
Pharvaris is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's promising pipeline and growth prospects have caught the attention of Wall Street analysts, contributing to the stock's recent momentum.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。